Curative, Organ-Sparing, Multimodal, Perioperative Treatment of a Young Patient with a Rectoanal Inflammatory Myofibroblastic Tumor

2021 ◽  
pp. 1-7
Author(s):  
Patrick Schöffski ◽  
Sara Vander Borght ◽  
Isabelle Vanden Bempt ◽  
Sander Jentjens ◽  
Vincent Vandecaveye ◽  
...  
Keyword(s):  
Inflammatory Myofibroblastic Tumor ◽  
Kinase Inhibitor ◽  
Locally Advanced ◽  
Young Female ◽  
Postoperative Treatment ◽  
Kinase Gene ◽  
Curative Intent ◽  
Sphincter Function ◽  
Anaplastic Lymphoma ◽  
Anaplastic Lymphoma Kinase Gene

<b><i>Introduction:</i></b> We report the case of a young female patient with a technically resectable, nonmetastatic, rectoanal, anaplastic lymphoma kinase gene (<i>ALK</i>)-translocated inflammatory myofibroblastic tumor (IMFT). <b><i>Case Presentation:</i></b> The patient was successfully treated preoperatively with the tyrosine kinase inhibitor (TKI) crizotinib, to downsize the primary tumor, followed by sphincter-sparing surgery, and adjuvant radiotherapy and crizotinib. She is now in follow-up with good sphincter function and with no evidence of active disease. <b><i>Conclusion:</i></b> Pre- and postoperative treatment administration of crizotinib can be given with curative intent to patients with locally advanced, nonmetastatic IMFTs to avoid mutilating surgery.

scholarly journals Anaplastic Lymphoma Kinase Gene Analysis as a Useful Tool for Identifying Primary Unknown Metastatic Lung Adenocarcinoma

2014 ◽  
Vol 53 (23) ◽  
pp. 2711-2715 ◽  
Author(s):  
Naoki Watanabe ◽  
Tomoya Ishii ◽  
Takayuki Takahama ◽  
Akira Tadokoro ◽  
Nobuhiro Kanaji ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Anaplastic Lymphoma Kinase ◽  
Gene Analysis ◽  
Kinase Gene ◽  
Anaplastic Lymphoma ◽  
Metastatic Lung ◽  
Anaplastic Lymphoma Kinase Gene

scholarly journals Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers

2020 ◽  
Vol Volume 13 ◽  
pp. 6927-6935
Author(s):  
De-Ning Ma ◽  
Xin-Yi Gao ◽  
Yi-Bo Dan ◽  
An-Ni Zhang ◽  
Wei-Jun Wang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Anaplastic Lymphoma Kinase ◽  
Gene Rearrangement ◽  
Kinase Gene ◽  
Anaplastic Lymphoma ◽  
Anaplastic Lymphoma Kinase Gene

scholarly journals EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer

2020 ◽  
Vol 50 (12) ◽  
pp. 1470-1474
Author(s):  
Beina Hui ◽  
Jingping Zhang ◽  
Xiaobo Shi ◽  
Fangfang Xing ◽  
Yang W Shao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Fusion Gene ◽  
Ovarian Cancer Cells ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Kinase Gene ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

Abstract Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress the growth of ovarian cancer cells and transplantation tumours. Here, we present a patient with metastatic ALK+ high-grade serous ovarian cancer that testing positive for EML4-ALK (microtubule-associated protein-like 4 gene, fused to the anaplastic lymphoma kinase gene), experienced dramatic benefit after administration of the anaplastic lymphoma kinase inhibitor alectinib. This is the first clinical evidence that treatment with alectinib may provide a personalized maximum benefit for patients with high-grade serous ovarian cancer who are positive for EML4-ALK.

Crizotinib and Testing for ALK

2011 ◽  
Vol 9 (12) ◽  
pp. 1335-1341 ◽  
Author(s):  
Alice T. Shaw ◽  
Benjamin Solomon ◽  
Mari Mino Kenudson
Keyword(s):  
Large Scale ◽  
Cost Effective ◽  
Screening Strategy ◽  
Current Standard ◽  
Multicenter Studies ◽  
Kinase Gene ◽  
Anaplastic Lymphoma ◽  
Anaplastic Lymphoma Kinase Gene ◽  
Diagnostic Modalities ◽  
Us Fda

Crizotinib was recently approved by the US FDA for the treatment of advanced non–small cell lung cancer (NSCLC) harboring the ALK (anaplastic lymphoma kinase) gene rearrangement. To ensure identification of patients most likely to benefit, the FDA approved crizotinib concurrently with a companion diagnostic test—the Vysis ALK Break Apart FISH Probe Kit. This kit was used in 1 of the 2 pivotal trials leading to the FDA approval of crizotinib and has become the gold standard for detecting ALK rearrangement in NSCLC. Although ALK FISH is clinically validated, the assay can be technically challenging and costly. Therefore, other diagnostic modalities are being explored, including immunohistochemistry (IHC) and reverse transcriptase–polymerase chain reaction. This article provides an overview of the diagnostic assays available for detecting ALK rearrangement. Each assay, including ALK FISH, has its strengths and weaknesses. Recent work with commercially available ALK antibodies suggests that IHC-based tests may represent a reliable and cost-effective screening strategy; however, large multicenter studies comparing IHC with FISH are needed to validate ALK IHC. While ALK FISH remains the current standard for diagnosing ALK positivity, large-scale screening of patients with newly diagnosed advanced NSCLC, as recommended by NCCN, may require development and validation of alternative screening strategies, such as combination IHC and FISH.

Sign in / Sign up

Export Citation Format

Share Document